The International journal on drug policy
September 9, 2026
Julian Heller, Yogi Hale Hendlin
A 2022 article in Nature proclaimed the possibility of "Taking the tripping out of psychedelic medicine," highlighting efforts to engineer medically-compliant designer psychedelics purportedly delivering mental health benefits without inducing subjective experiences. Such developments have since initiated a new mainstream in the pharmaceuticalization and commodification of psychedelics. These...
The International journal on drug policy
August 1, 2026
Myfanwy Graham, Yimin Ge, Rosalie Liccardo Pacula et al.
1 citation
We know little about the extent psychedelic substances are consumed therapeutically and/or discussed with medical professionals despite renewed global interest in these substances. We examined self-reported responses from the 2023 International Cannabis Policy Study (ICPS) in repeated cross-sectional surveys in Canada, the United States, Australia, and New Zealand. The survey included questions...
The International journal on drug policy
July 9, 2026
François Gagnon, Anne Philibert, Benjamin Carignan et al.
Psychedelic retail stores illegally selling psilocybin, DMT and related substances have proliferated in Canada, with close to 60 brick-and-mortar shops documented in 2023. This echoes the pre-legalization and regulation cannabis landscape. Public responses have remained inconsistent, oscillating between de facto tolerance and enforcement of the law, raising concerns among public health...
The International journal on drug policy
July 8, 2026
Laetitia Vanderijst, Jean-Luc Faillie, Thibault Mura et al.
Imperfect blinding is not specific to psychedelic trials. In randomized trials, treatment allocation is frequently correctly guessed, yet blinding integrity is rarely assessed outside of psychedelic research and is generally not considered a barrier in regulatory evaluation. The intense debate in psychedelics may reflect a broader double standard affecting mental health research, when...
The International journal on drug policy
July 1, 2026
Alex K. Gearin, I Glenn Cohen, Albert Garcia‐romeu
1 citation
The revival of psychedelic medicalization is often narrated as a story of scientific legitimacy and neurotherapeutic promise, yet the unusual sensitivity of psychedelics to environmental conditions has encouraged research on music, therapy, setting, and other contextual factors. Treating setting and context as the building blocks of felt atmospheres, this article examines how regulation...
The International journal on drug policy
July 1, 2026
Salim Mezaache, Liselotte Pochard, Hélène Peyrière et al.
Ketamine analogues are emerging dissociative substances structurally related to ketamine and increasingly detected on drug markets worldwide. This study aimed to characterize patterns of use, user profiles, and associated health outcomes in France. We conducted a retrospective analysis of cases involving ketamine analogues reported to the French Addictovigilance Network up to 31 December 2024....
The International journal on drug policy
June 1, 2026
Juan Carlos Mendoza-Pérez, Keith J Watts
Poppers (alkyl nitrites) are widely used among sexually diverse men to enhance sexual pleasure. However, research has historically been dominated by risk-centered frameworks such as associations with HIV or other STIs, overlooking user motivations related to hedonic reward, intimacy, and agency. This conceptual oversight is particularly evident in the Global South. This study explores the...
The International journal on drug policy
2026
Christina Chwyl, Adrianne R Wilson-Poe, Kim Hoffman et al.
3 citations
There remain significant gaps in knowledge about best practices for facilitated psychedelic care and psychedelic-assisted therapy. To inform the development of service models that support safe and beneficial experiences, this qualitative study explored expert perspectives on current and ideal standards of care, including key practices (e.g., screening, adapting care to diverse contexts) and...
The International journal on drug policy
2026
Guy Simon, Nir Tadmor, Demian Halperin
2 citations
Psychedelics induce transformative experiences leading to lasting changes in attitudes and behaviour, with outcomes depending on both pharmacological factors and the context of the experience ('set and setting'), marking a paradigm shift in mental health treatment. As psychedelics transition from traditional contexts to clinical settings, tension emerges between authenticity and...
The International journal on drug policy
December 1, 2025
Tereza Dleštíková
This paper proposes a psychedelic theory of desistance, arguing that psychedelic-assisted therapy (PAT) may support the desistance from crime - the cessation of criminal behavior - by promoting identity transformation and personal meaning-making among criminal justice-involved individuals. Drawing from psychedelic science and desistance focused criminological theories, it suggests that, when...
The International journal on drug policy
November 1, 2025
Mauricio Sepúlveda Galeas, Ernesto Escobar, Sebastían Ubiergo Scheel et al.
3 citations
This article critically examines the 'Tuci' (or "pink cocaine") phenomenon as an epistemic, cultural, and pharmacopolitical object, proposing its conceptualization as a monstrous substance. Two common assumptions in institutional and media discourses are problematized: that 'Tuci' is a counterfeit of 2C-B and that its identity is defined by the presence of ketamine. Using an approach that...
The International journal on drug policy
November 1, 2025
Liam O Jarvis, Alexander H Jack, Niall Galbraith et al.
1 citation
The global prevalence of depression is high, and there are concerns about the therapeutic effectiveness of current treatments. Research over the past two decades has led to a new class of alternative treatments termed 'psychedelic-assisted therapy (PAT).' This study aimed to investigate the attitudes toward the application and use of psychedelic-assisted therapies in the United Kingdom...
The International journal on drug policy
November 1, 2025
Deirdre Mongan, Nicki Killeen, Seán R Millar et al.
Hexahydrocannabinol (HHC) is a semi-synthetic cannabinoid which was marketed and sold openly in Ireland as a legal alternative to cannabis products until it was controlled in July 2025. There have been reports of psychotic illness precipitated by HHC use. Consequently, there are fears that HHC may become a public health issue. This study's aim was to measure the extent of HHC use and patterns...
The International journal on drug policy
November 1, 2025
Dara Ruane
Prohibition-based drug policies such as recent UK draft legislation on recreational drug possession assume expanding police powers will deter use and thereby reduce harm. In fact research suggests punitive policing harms PWUD (people who use drugs) in recreational contexts by incentivising behaviours with lower legal but higher health risk. Although some vectors of this harm have been well...
The International journal on drug policy
August 1, 2025
Ilze Mj Thoonen, Saskia J. Rietjens, Arjen Koppen et al.
1 citation
The use of psychoactive drugs has been increasing worldwide, with adolescents and young adults accounting for a large share of people who use drugs. To date, there is limited information on trends of intoxications with psychoactive drugs among adolescents, particularly with regard to New Psychoactive Substances (NPS). A retrospective study was performed from 2014-2023 to characterize...
The International journal on drug policy
June 1, 2025
Joseph J Palamar
7 citations
Ketamine-related poisonings and law enforcement seizures have been increasing in the United States, but population surveys suggest that recreational use has been rare with trends being relatively stable. This study aimed to estimate trends and correlates of use among nightclub attendees-a population known for high prevalence of party drug use. Adults entering randomly selected nightclubs in New...
The International journal on drug policy
February 1, 2025
Jason Hughes, Joshua Stuart-Bennett, Michael Dunning et al.
2 citations
Existing research highlights an increase in psychedelic microdosing, particularly for therapeutic purposes and as a means for self-enhancement. However, we know little about the different routes into and out of microdosing, particularly by those who do not consume other illicit substances, and of the processes involved in the development, maintenance, and cessation of practices. Drawing upon a...
The International journal on drug policy
November 1, 2024
Rodolfo Olivieri, Luís Fernando Tófoli
1 citation
This essay examines the combination of psychoanalytic therapy and psychedelic substances in mid-20th century Argentina. Through document analysis, it examines the intersection of psychedelics and psychoanalysis, drawing from historical texts and writings by local psychoanalysts to develop a comprehensive understanding of the distinctive clinical practices and therapeutic approaches in the...
The International journal on drug policy
August 1, 2024
Stephanie Lake, Philippe Lucas
31 citations
Despite advancements in policies governing psychedelic substances globally, our understanding of real-world psychedelic use and its variations across international jurisdictions remains limited. We implemented the Global Psychedelic Survey (GPS) to capture information about psychedelic consumer characteristics, access, and usage patterns around the world. The GPS was administered online in...
The International journal on drug policy
July 1, 2024
Masoomeh Maarefvand, Maziyar Ghiabi
In this essay we want to foreground a question: what happens to 'addiction' when we take seriously cultural scripts informing its trajectories? Can this bring us to unthink addiction as problematic notion and move it onto new paradigms that fit better the now acknowledged fluidity and pluralistic episteme of 'addiction' and more broadly of chronic life conditions? Indeed, 'addiction' has become...
The International journal on drug policy
2024
Leigh Coney, Amy Peacock, Aili Malm et al.
2 citations
Drug use and trading are typically social activities; however, supply through cryptomarkets can occur without any in-person social contact. People who use drugs alone may be at higher risk of experiencing harms, for example, due to lack of others who may call for emergency assistance. Alternatively, cryptomarkets may be a source of harm reduction information and drugs with better-known content...
The International journal on drug policy
August 1, 2023
Tayler Holborn, Fabrizio Schifano, Paolo Deluca
15 citations
The proliferation of Novel Psychoactive Substances (NPS) presents a challenge for global drug policy. The ease of online drug purchase and the emergence of the dark web have created new avenues for the growth of NPS. Despite the global nature of this issue, limited research has examined motivations of use. These include perceived safety or convenience, an interest in novel pharmacology and...
The International journal on drug policy
May 1, 2023
Joseph J Palamar, Austin Le, Charles M Cleland et al.
41 citations
Drug use is prevalent among people who attend electronic dance music (EDM) parties at nightclubs or festivals. This population can serve as a sentinel population to monitor trends in use of party drugs and new psychoactive substances (NPS) that may diffuse through larger segments of the population. We surveyed adults entering randomly selected EDM parties at nightclubs and dance festivals in...
The International journal on drug policy
April 1, 2023
George Henry Robert Simpson, Caroline Chatwin, Elke van Hellemont
4 citations
This article presents an exploration of naturally occurring Class-A magic mushroom markets in the UK. It aims to challenge some of the mainstream narratives about drug markets and to identify features of this specific market, which will extend our understanding of how illegal drug markets operate and are structured more generally. The research presented comprises a three year ethnography of...
The International journal on drug policy
December 1, 2022
Maxim Tvorun-Dunn
20 citations
The history of psychedelia within the New Left counterculture often implies a cultural alignment between psychedelics and progressive values or the promise of radical communitarian social reform. In contrast to these potentials, this paper examines Silicon Valley's engagement with psychedelics, a community which has demonstrated considerable financial and personal interests in these drugs...